miR-19a acts as an oncogenic microRNA and is up-regulated in bladder cancer

Feng, Ying; Li, Jun; Kang, Yongming; He, Yue; Liang, Bo; Yang, Ping; Zhou, Yu

doi:10.1186/s13046-014-0067-8

Cited by 99 publications

(31 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, upregulation of miR-19a in tissues and plasma samples from patients with BC has been reported, and this miRNA has been shown to act as an oncogene by targeting PTEN, which may have a significant role in human BC. 52,53 miRNA expression signatures of RCC We also reviewed six recently published miRNA expression signatures comparing RCC and normal kidney tissue using clinical specimens (Table 3). [18][19][20][21][22][23] Two signatures were constructed from deep sequencing and the other four signatures were constructed from microarrays.…”

Section: Downregulated Mirnas In Multiple Bc Signaturesmentioning

confidence: 99%

Aberrantly expressed microRNAs in bladder cancer and renal cell carcinoma

et al. 2016

View full text Add to dashboard Cite

Bladder cancer (BC) and renal cell carcinoma (RCC) are frequently diagnosed urinary tract cancers. Recently developed molecular-targeted therapies for RCC have shown remarkable therapeutic efficacy; however, no targeted therapeutics are currently approved for the treatment of BC, and few effective treatment options exist. Current studies have shown that small noncoding RNA molecules have major roles in cancer cells. MicroRNAs (miRNAs) are endogenous small noncoding RNA molecules that regulate protein-/nonprotein-coding RNAs in human cells. A large body of evidence suggests that aberrantly expressed miRNAs are deeply involved in the pathogenesis of human cancers. In this paper, we review recently published miRNA expression signatures of BC and RCC. We focus on downregulated or upregulated miRNAs in multiple signatures and discuss putative target genes of miRNAs. Comparisons of RCC and BC expression signatures revealed that the two types of cancer showed opposite expression patterns for miR-200 family miRNAs (i.e., miR-141/200c and miR-200a/200b/429). We discuss in silico analysis of genes targeted by miR-200 family miRNAs and the molecular mechanisms underlying BC and RCC.

show abstract

Section: Downregulated Mirnas In Multiple Bc Signaturesmentioning

confidence: 99%

Aberrantly expressed microRNAs in bladder cancer and renal cell carcinoma

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Similar with other members in this cluster, miR-19a has been reported to be dysregulated in various human cancers, such as laryngeal squamous cell carcinoma, breast cancer, non-small cell lung cancer, gastric cancer, colorectal cancer, cervical carcinoma, and bladder cancer. [39][40][41][42] Especially, Han et al 43 observed the downregulation of miR-19a in primary HCC samples of patients who had developed HCC recurrence compared to those with non-recurrence, implying that this miRNA might function as a tumor suppressor in HCC. Cyclin D1, located within chromosome 11q13, belongs to the G1 cyclin family and plays a role in regulating the transition through the G1 phase of the cell cycle.…”

Section: Reverse Correlation Between Mir-19a and Cyclin D1 Expressionmentioning

confidence: 99%

A systematic investigation based on microRNA-mediated gene regulatory network reveals that dysregulation of microRNA-19a/Cyclin D1 axis confers an oncogenic potential and a worse prognosis in human hepatocellular carcinoma

Zhang

Guo²,

Li³

et al. 2015

RNA Biology

View full text Add to dashboard Cite

MicroRNAs (miRNAs) contribute to a wide variety of human diseases by regulating gene expression, leading to imbalances in gene regulatory networks. To discover novel hepatocellular carcinoma (HCC)-related miRNA-target axes and to elucidate their functions, we here performed a systematic investigation combining biological data acquisition and integration, miRNA-target prediction, network construction, functional assay and clinical validation. As a result, a total of 117 HCC differentially expressed miRNAs were identified, and 728 high confident target genes of these miRNAs were collected. Then, the interaction network of target genes was constructed and 221 key nodes with topological importance in the network were identified according to their topological features including degree, node-betweenness, closeness and K-coreness. Among these key nodes, Cyclin D1 had the highest node-betweenness, implying its bottleneck role in the network. Luciferase reporter assay confirmed that miRNA-19a, which was one of HCC downregulated miRNAs, directly targeted Cyclin D1 in HCC cells. Moreover, miR-19a might play inhibitory roles in HCC malignancy via regulating Cyclin D1 expression. Further clinical evidence also highlighted the prognostic potential of miR-19a/Cyclin D1 axis in HCC. In conclusion, this systematic investigation provides a framework to identify featured miRNAs and their target genes which are potent effectors in the occurrence and development of HCC. More importantly, miR-19a/Cyclin D1 axis might have promising applications as a therapeutic target and a prognostic marker for patients with HCC.

show abstract

“…[5][6][7][8] The prognosis of BCa patients is closely related to the clinical stage of BCa, but the specific early-stage symptoms for BCa patients are unclear. [9][10][11][12] Thus, it is still urgent to differentiate novel biomarkers for the early diagnosis and efficient treatment for BCa patients.…”

Section: Introductionmentioning

confidence: 99%

Long non-coding RNA ARAP1-AS1 promotes the progression of bladder cancer by regulating miR-4735-3p/NOTCH2 axis

Teng

Jia

et al. 2018

Cancer Biology & Therapy

View full text Add to dashboard Cite

Accumulative reports have documented the critical functions of long non-coding RNAs (lncRNAs) in the progression of malignant tumors, including bladder cancer (BCa). LncRNA ARAP1-AS1 was chosen to be the object of this study due to it was significantly upregulated in the BCa samples of TCGA database. qRT-PCR further validated the dysregulation of ARAP1-AS1 in 88 pairs of BCa tissues and six BCa cells. Kaplan Meier analysis was utilized to analyze the prognostic value of ARAP1-AS1 for patients with BCa. To evaluate the oncogenic property of ARAP1-AS1 in bladder cancer, loss-of-function assays were conducted in two BCa cells in which ARAP1-AS1 was expressed highest. Mechanically, ARAP1-AS1 was enriched in the cytoplasm of BCa cells, suggesting that ARAP1-AS1 might act as a ceRNA to regulate gene expression and biological processes in bladder cancer. It was certified that ARAP1-AS1 can bind with miR-4735-3p in BCa cells. Moreover, functional assays supported the hypothesis that miR-4735-3p is a tumor suppressor in BCa. Additionally, NOTCH2 mRNA could be targeted by miR-4735-3p in BCa cells. The results of all mechanism experiments indicated that ARAP1-AS1 regulated miR-4735-3p/NOTCH2 axis in BCa by acting as a ceRNA. All our research findings may bring novel insights into the treatment of bladder cancer. ARTICLE HISTORY

show abstract

miR-19a acts as an oncogenic microRNA and is up-regulated in bladder cancer

Cited by 99 publications

References 42 publications

Aberrantly expressed microRNAs in bladder cancer and renal cell carcinoma

Aberrantly expressed microRNAs in bladder cancer and renal cell carcinoma

A systematic investigation based on microRNA-mediated gene regulatory network reveals that dysregulation of microRNA-19a/Cyclin D1 axis confers an oncogenic potential and a worse prognosis in human hepatocellular carcinoma

Long non-coding RNA ARAP1-AS1 promotes the progression of bladder cancer by regulating miR-4735-3p/NOTCH2 axis

Contact Info

Product

Resources

About